Overview
- Combat Sports Anti-Doping announced Hafez accepted a twelve-month period of ineligibility under the UFC Anti-Doping Policy.
- A WADA-accredited lab detected the prohibited peptide ipamorelin in an out-of-competition sample collected from Hafez on March 20, 2026.
- CSAD’s review found no evidence of intentional use but said Hafez acted with gross negligence by taking a clinic-provided product without adequate due diligence.
- The suspension is retroactive to the March 20 sample date, making Hafez eligible to compete again on March 20, 2027, and he has been cooperating with the investigation.
- The case highlights risks from third-party clinic or supplement products and comes as UFC testing transitions to CSAD with samples collected by DFSI and analyzed at SMRTL.